Larimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain Disorders

Rhea-AI Summary

Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced that preclinical studies on CTI-1601’s impact on gene expression and neurodegeneration will be showcased at the Gordon Research Conference on Neurobiology of Brain Disorders from August 7-12, 2022. The poster, titled "Mitochondrial Protein Frataxin (FXN) promotes Expression of Neuronal Differentiation Markers," will be presented by David Bettoun, Ph.D., Vice President of Discovery and Non-clinical R&D. Larimar focuses on developing treatments for complex rare diseases, including Friedreich's ataxia.

Positive

• CTI-1601's preclinical studies may enhance understanding of its therapeutic potential for neurodegeneration.
• Presentation at a reputable conference may increase visibility and credibility among investors and scientists.

Negative

• None.

BALA CYNWYD, Pa., July 28, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that preclinical studies evaluating CTI-1601’s effects on gene expression and neurodegeneration will be featured in a poster at the upcoming Gordon Research Conference on Neurobiology of Brain Disorders. The conference will take place August 7 – 12, 2022 at the Rey Don Jaime Grand Hotel in Castelldefels, Spain.

The poster, entitled, “Mitochondrial Protein Frataxin (FXN) promotes Expression of Neuronal Differentiation Markers: Effect of FXN Supplementation in a Model of Leukodystrophy,” will be available for viewing throughout the duration of the conference. The poster’s presenting author is David Bettoun, Ph.D., Vice President of Discovery and Non-clinical R&D, Larimar Therapeutics.

About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569

Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715

FAQ

What is the focus of Larimar Therapeutics?

Larimar Therapeutics focuses on developing treatments for complex rare diseases.

What is the significance of CTI-1601 in Larimar's research?

CTI-1601 is being developed as a potential treatment for Friedreich's ataxia.

When will Larimar present its preclinical study findings?

Larimar will present its findings at the Gordon Research Conference from August 7-12, 2022.

Who is presenting the poster on CTI-1601?

David Bettoun, Ph.D., Vice President of Discovery and Non-clinical R&D, will present the poster.

What are the expected outcomes of the studies on CTI-1601?

The studies aim to assess the effects of CTI-1601 on gene expression and neurodegeneration.